{
    "3963": "when not all exacerbation events occurred during the viral infection",
    "3855": "viral infection increases airway inflammation which aggravates disease symptoms",
    "3856": "Recent advances in in vitro air-liquid interface 3D cultures",
    "3854": "Respiratory virus infection",
    "3857": "recent findings of viral interaction with the upper airway",
    "3858": "recent data regarding viral interactions with the airway epithelium",
    "3859": "potential exacerbation mechanisms and the associated viruses",
    "3860": "recent data regarding viral interactions with the airway epithelium",
    "3861": "the understanding of viral induced exacerbation in chronic airway inflammatory diseases",
    "3862": "airway inflammation",
    "3863": "upper airway",
    "3864": "complexity and heterogeneity of the disease",
    "3865": "impaired bacterial immune response",
    "3866": "interplay between virus and pathogenic bacteria",
    "3867": "morbidity and sometimes mortality in patients",
    "3869": "the presence of environmental factors",
    "3870": "infiltration of activated immune cells",
    "3871": "viral infection",
    "3872": "equally high",
    "3873": "their ease of transmission and infection",
    "3874": "disruption of tight junctions",
    "3875": "in order to properly manage exacerbations via supplementary treatments",
    "3876": "dysregulated inflammation",
    "3877": "the upper airway",
    "3878": "recent findings of viral interaction with the upper airway",
    "3879": "chronic airway inflammatory disease exacerbations",
    "3880": "ease of transmission and infection",
    "3881": "more viruses were recovered during acute exacerbations events",
    "3882": "RV, RSV, and IFV",
    "3883": "parainfluenza virus",
    "3884": "respiratory viruses",
    "3885": "they can infect both the upper and/or lower air",
    "3886": "within airway epithelial cells",
    "3887": "the cells release antiviral factors and cytokines",
    "3888": "type 1 inflammatory responses",
    "3891": "impaired or aberrant",
    "3892": "recent novel findings",
    "3893": "to provide further understanding of viral induced exacerbation",
    "3894": "current scarcity of antiviral drugs for the management of viral-induced exacerbations",
    "3941": "viruses evoke an inflammatory response as a means of counteracting the infection",
    "3942": "inflammatory",
    "3943": "rapid type 1 immunity",
    "3944": "enhance granulocyte infiltration thus prolonging the exacerbation symptoms",
    "3945": "viral infections",
    "3946": "worsens the classical symptoms of disease",
    "3947": "more neutrophilic in nature",
    "3948": "IL-25, IL-33 and TSLP",
    "3949": "ILC2s",
    "3950": "massive damage",
    "3951": "work in concert to activate ILC2s",
    "3952": "increased ILC2 activation",
    "3954": "do not activate an ILC2 response",
    "3960": "increase neutrophilic activation",
    "3961": "worsens the symptoms of airway diseases",
    "3962": "viral infection with other sensitizing agents",
    "3964": "the nasal epithelium remains the primary site of most infections",
    "3965": "a more complex interplay between the virus and upper airway epithelium",
    "3966": "exacerbation of their symptoms",
    "3967": "high morbidity and even mortality worldwide",
    "3968": "to determine the contribution of the microbiome and mycobiome to viral infections",
    "3969": "recent data regarding viral interactions with the airway epithelium",
    "3970": "Patients with chronic airway inflammatory diseases",
    "3971": "type 2-skewed inflammatory response",
    "3972": "weak type 1 inflammation-inducing viruses",
    "3973": "massive damage and cell death to the epithelial barrier",
    "3974": "prolong airway inflammation",
    "3975": "enhance granulocyte infiltration thus prolonging the exacerbation symptoms",
    "3976": "human papilloma virus",
    "3977": "the role of HPV infection in causing chronic inflammation in the airway",
    "3978": "continuous expression of antiviral genes",
    "3979": "cause the virus to linger longer in the airway",
    "3980": "airway microbiome",
    "3981": "19 virus)",
    "3982": "massive damage and cell death to the epithelial barrier",
    "3983": "further compounds the cell deaths in IFV infected epithelium",
    "3984": "further contact with other pathogens and allergens in the airway",
    "3985": "promote further epithelial remodeling during its regeneration",
    "3986": "receive their annual influenza vaccination",
    "3987": "induction of vasodilation or tight junction opening factors",
    "3988": "disruption of tight junctions",
    "3989": "weak type 1 inflammation-inducing viruses",
    "3990": "the expression of vasodilating factors and fluid homeostatic factors",
    "3991": "relationship between asthma and COPD exacerbations",
    "3992": "specific bacterial species in the microbiome",
    "3993": "the effect induced by the virus may destabilize the equilibrium of the microbiome present",
    "3994": "the epithelial barrier in the airways",
    "3995": "impaired bacterial immune response",
    "3996": "more far reaching effect",
    "3997": "synergistic effect of viral infection with other sensitizing agents",
    "3998": "efficacy in the treatments of irritable bowel syndrome by restoring the intestinal microbiome",
    "3999": "increase neutrophilic activation",
    "4000": "The upper airway epithelium",
    "4001": "increase contact between environmental triggers with the lower airway and resident immune cells",
    "4002": "oxidative stress",
    "4003": "modulation of miRNAs and epigenetic modification",
    "4004": "growth of pathogenic bacteria",
    "4005": "inflammation and alteration of the lower airway environment",
    "4006": "RV, RSV, and IFV",
    "4007": "directly destroy the cilia of the ciliated cells",
    "4008": "disrupt the equilibrium of the mucociliary function following viral infection",
    "4009": "more foreign material and allergen to enter the airway",
    "4010": "short non-coding RNAs",
    "4011": "viral infections",
    "4012": "circulating miRNA changes",
    "4013": "viral infections",
    "4014": "increase miR-21 and augmented inflammation in experimental murine asthma models",
    "4015": "induce oncostatin M (OSM) which causes tight junction opening",
    "4016": "miR-22 was shown to be suppressed",
    "4017": "targets to modulate viral induced airway changes",
    "4018": "epigenetic modification",
    "4019": "the association of epigenetic modification and chronic airway inflammatory diseases",
    "4020": "miRNA changes in contributing to exacerbations",
    "4021": "IFNγ epigenetically modifies the viral resistance of epithelial cells",
    "4022": "an altered inflammatory state",
    "4023": "increase neutrophilic activation",
    "4024": "constant oxidative stress",
    "4025": "trigger the further production of ROS as an antiviral mechanism",
    "4026": "infiltrating cells",
    "4027": "increases airway inflammation",
    "4028": "important information",
    "4029": "epithelial cell models",
    "4030": "to identify systemic mechanisms of acute exacerbation",
    "4031": "the humanized mouse model that possess human immune cells",
    "4032": "the best mode of verification of the associations of the virus",
    "3868": "complex interactions between the host and the exacerbation agents",
    "3687": "long non-coding RNAs (lncRNAs)",
    "3688": "to calculate the relevance between lncRNA and protein in a heterogeneous network",
    "3689": "protein-protein interaction",
    "3690": "regulates cell cycle and survival",
    "941": "Western blot analysis",
    "933": "mosquitoes",
    "934": "acute and fatal encephalitis",
    "935": "35%",
    "936": "10%",
    "937": "polyclonal",
    "938": "differential alterations in VEEV-infected astrocytes",
    "939": "endoplasmic reticulum (ER) stress",
    "940": "three classes of sensors",
    "942": "Hs00152928_m1",
    "943": "early growth response protein 1",
    "557": "2012",
    "558": "52%)",
    "559": "47.7% were females",
    "560": "Dromedary camels",
    "562": "11-13 days",
    "563": "16 days",
    "564": "supportive and symptomatic",
    "565": "between 41 and 60 years",
    "279": "pyrin domain-containing 3",
    "280": "lipopolysaccharide-primed macrophages",
    "281": "K + efflux",
    "282": "transmembrane pore-forming viral proteins",
    "283": "Betacoronavirus",
    "284": "Coronaviridae",
    "285": "remains unknown",
    "287": "single-stranded",
    "288": "8,098",
    "289": "9.6%,",
    "290": "interleukin 1 beta (IL-1β) and IL-",
    "292": "by sensing the cellular damage or distress induced by viroporins",
    "293": "76",
    "294": "Ca 2+ -permeable",
    "296": "NLRP3 inflammasome",
    "257": "7.3 billion",
    "248": "Middle East respiratory syndrome coronavirus",
    "249": "Transmissibility and severity",
    "250": "January 30, 2020",
    "251": "H7N9",
    "252": "a series of modeling articles",
    "253": "proportion of individuals who become ill with or die from a disease in a population",
    "254": "20%",
    "255": "less than 1",
    "1657": "35 000 to 60 000",
    "1635": "various biological processes",
    "3258": "Nuclear receptors (NRs)",
    "3259": "a class of ligand-inducible transcription factors",
    "3260": "homeostasis, differentiation, embryonic development, and organ physiology",
    "3261": "seven",
    "3262": "a reliable 3D (three dimensional) structure of the target protein",
    "3263": "X-ray crystallography",
    "3264": "time-consuming and expensive",
    "3265": "membrane proteins",
    "3266": "KEGG",
    "546": "HFRS",
    "547": "enveloped, negative-sense RNA virus",
    "548": "rodents",
    "549": "plasma viral load",
    "551": "antiviral medicine",
    "552": "IFITM3 SNP rs12252 C allele and CC genotype",
    "554": "IFITM1, 2, and 3",
    "555": "restriction of viral entry into cells",
    "556": "rs12252 C allele",
    "2754": "RP transmission model",
    "2755": "Reservoir-People (RP) transmission network model",
    "2756": "2.30 from reservoir to person and 3.58 from person to person",
    "2757": "we developed a Bats-Hosts-Reservoir-People",
    "2758": "calculating the basic reproduction number",
    "2759": "The BHRP transmission network model was based on the following assumptions or facts",
    "2760": "four",
    "2761": "four",
    "2762": "the seafood market",
    "2763": "five compartments",
    "2764": "5.2 days",
    "2765": "5-day",
    "2766": "3 to 7 days",
    "2767": "5.8 days",
    "2768": "0.5 times that of symptomatic infection",
    "2769": "0.3 million",
    "2770": "2.87 million",
    "2771": "the expected number of secondary infections",
    "2772": "basic reproduction number",
    "2773": "0.8-1.3",
    "2774": "2.5-7.2",
    "2775": "decrease R 0 .",
    "2776": "potential transmission from the infection source (probably be bats) to the human infection",
    "2777": "calculating the basic reproduction number",
    "5149": "cause hemorrhagic fevers in humans",
    "5150": "Old World (OW) and New World (NW)",
    "5151": "The OW Lassa virus",
    "5152": "live attenuated",
    "5153": "because lung epithelial cells are one of the initial cell targets of humans",
    "5154": "1 day",
    "5155": "Ouabain",
    "5156": "ATP1A1",
    "5157": "Combination therapy",
    "5158": "ATP1A1 and PHB",
    "5159": "using genetics and pharmacological inhibition of the genes",
    "5175": "mild skin infections to fatal necrotizing pneumonia",
    "5176": "8-30%",
    "5177": "tissue resident alveolar macrophages",
    "5178": "The subsequent infection with Gram-positive bacteria",
    "5179": "Reduced TNFα production by NK cells",
    "5180": "dPly",
    "5181": "imbalances in microbial composition",
    "568": "interferon-induced transmembrane",
    "569": "three",
    "570": "2BP",
    "571": "IFITM5 with FKBP11",
    "572": "immune system activity",
    "573": "S-palmitoylation on the protein",
    "574": "bonerestricted IFITM-like (BRIL) protein",
    "575": "two molecules do not interact with each other",
    "576": "sequence identity",
    "577": "amino acid sequence identity",
    "580": "aspartate",
    "5256": "11 June 2009",
    "5257": "1/40",
    "5258": "conferring 50% protection against a viral challenge",
    "5259": "based only on serological analysis of paired sera",
    "5260": "residual signature of the remote exposure of these individuals to H1N1 viruses",
    "5261": "week 38",
    "3267": "11,399",
    "3268": "49.2%",
    "3269": "2.2%)",
    "3270": "2005",
    "3271": "cough, rhinitis, fever and other common clinical symptoms",
    "3272": "(≤14 years old",
    "3273": "1.82:1",
    "4077": "to comprehensively investigate the viral epidemiology of adult RTIs",
    "4078": "1",
    "4079": "4.1% of cases",
    "4080": "parainfluenza infection, old age, and immunosuppression",
    "4081": "PCR/ ESI-MS",
    "4082": "if the patients met one of the following conditions",
    "4083": "9-month",
    "4084": "263",
    "4085": "rhinovirus",
    "917": "31 kb",
    "918": "single-stranded, linear, and nonsegmented RNA",
    "919": "30,847",
    "920": "20kb nucleotides",
    "921": "5=",
    "502": "Pneumonia",
    "504": "Improved socioeconomic status and vaccinations",
    "507": "81%",
    "510": "605 million in 2000 to 664 million in 2015",
    "511": "25%",
    "512": "25%",
    "513": "0.015 episodes per child year",
    "514": "81%",
    "515": "0.015 episodes per child year",
    "516": "contribute to substantial morbidity across the life course",
    "517": "empyema",
    "518": "lung ultrasound",
    "520": "Widespread use of pneumococcal conjugate vaccination",
    "521": "17%",
    "522": "presumed bacterial pneumonia",
    "524": "65%",
    "530": "pneumococcal serotypes",
    "532": "pneumococcal conjugate vaccination",
    "533": "ambulatory pneumonia",
    "534": "S. pneumoniae and H. influenzae type B",
    "535": "antibody levels drop sharply after birth",
    "536": "morbidity and mortality",
    "537": "Markers of undernutrition",
    "538": "increases odds of pneumonia by 1.6 times",
    "539": "Markers of undernutrition",
    "540": "68%.",
    "541": "Influenza vaccination during pregnancy is safe",
    "923": "a rare complication of pneumonia",
    "4573": "a dense or fluffy opacity",
    "5163": "point mutations on immunodominant regions of surface proteins",
    "5164": "a positive-sense single stranded RNA enveloped virus causing chronic hepatitis",
    "5165": "about 3,000 aminoacids",
    "5166": "NS1 and NS2",
    "5167": "high mutation rate",
    "5168": "envelope glycoproteins E1 and E2",
    "5169": "based on antigenic differences of their nucleoprotein and matrix protein",
    "5170": "influenza A",
    "2477": "Category C pathogen",
    "2471": "Chikungunya fever",
    "2470": "a mosquito-borne pathogen",
    "2472": "Currently, there is no vaccine or antiviral treatment",
    "2473": "nominates a possible vaccine approach against CHIKV infection",
    "2474": "a mosquito-borne pathogen",
    "2475": "mosquito-borne disease",
    "2476": "primarily by Aedes aegypti",
    "2478": "Kimakonde",
    "2479": "''that which contorts or bends up''",
    "2480": "the illness of the bended walker",
    "2481": "in a sylvatic cycle",
    "2482": "Ae. aegypti and Ae. albopictus",
    "2483": "in an urban cycle",
    "2484": "The 2005-2006 epidemic of CHIKV in La Reunion islands",
    "2485": "over 46,000",
    "2486": "the epidemiology and global expansion of CHIKV",
    "2487": "evidence supporting these concepts",
    "2488": "three",
    "2489": "gene sequences of an Envelope protein",
    "2490": "between 50 and 310 y ago",
    "2491": "between 50 and 310 y ago",
    "2492": "CHIKV has come a long way",
    "2493": "Indian epidemic in 2005-2006",
    "2494": "Kerala isolate",
    "2495": "2-6 d",
    "2496": "4-7 d",
    "2497": "two rounds of translation",
    "2498": "decreased dexterity, loss of mobility, and delayed reaction",
    "2499": "40%",
    "2500": "polyarthralgia",
    "2501": "children",
    "2502": "joint pain",
    "2503": "More than 50%",
    "2504": "more than 33%",
    "2505": "children",
    "2506": "massive outbreaks",
    "2507": "complex replication cycle",
    "2508": "CHIKV",
    "2509": "an ecological pressure",
    "2510": "supplement Ae. aegypti as its primary vector",
    "2511": "Ae. albopictus",
    "2512": "34%",
    "2513": "tropical Africa",
    "2514": "Indian Ocean Islands outbreak",
    "2515": "an increase in infectivity of Ae. albopictus",
    "2516": "Ae. albopictus",
    "2517": "100 times more infective",
    "2518": "Ae. albopictus",
    "2519": "over 300 y",
    "2520": "common in urban areas",
    "2521": "about 50%",
    "2522": "CHIKV transmission from mother to fetus causing congenital illness and fetal death",
    "2523": "it is associated with a high degree of morbidity",
    "2524": "motherto-child transmission most likely happens transplacentally shortly before delivery",
    "2525": "nineteen cases of neonatal infection",
    "2526": "nominates a possible vaccine approach against CHIKV infection",
    "2527": "nominates a possible vaccine approach against CHIKV infection",
    "2528": "Category C pathogen",
    "2529": "improved safety profile",
    "4221": "Strong recommendation",
    "328": "Frequent and severe",
    "329": "bronchitis, pneumonia and bronchiolitis",
    "330": "NK cells",
    "331": "Excessive reactive oxygen species",
    "332": "ROS"
}